PMID- 31756900
OWN - NLM
STAT- MEDLINE
DCOM- 20200413
LR  - 20200413
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 20
IP  - 23
DP  - 2019 Nov 20
TI  - Targeting Tumor Endothelial Cells with Nanoparticles.
LID - 10.3390/ijms20235819 [doi]
LID - 5819
AB  - Because angiogenesis is a major contributor to cancer progression and metastasis, 
      it is an attractive target for cancer therapy. Although a diverse number of small 
      compounds for anti-angiogenic therapy have been developed, severe adverse effects 
      commonly occur, since small compounds can affect not only tumor endothelial cells 
      (TECs), but also normal endothelial cells. This low selectivity for TECs has 
      motivated researchers to develop alternate types of drug delivery systems (DDSs). 
      In this review, we summarize the current state of knowledge concerning the 
      delivery of nano DDSs to TECs. Their payloads range from small compounds to 
      nucleic acids. Perspectives regarding new therapeutic targets are also mentioned.
FAU - Sakurai, Yu
AU  - Sakurai Y
AD  - Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, 260-8675, 
      Chiba, Japan.
FAU - Akita, Hidetaka
AU  - Akita H
AD  - Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, 260-8675, 
      Chiba, Japan.
FAU - Harashima, Hideyoshi
AU  - Harashima H
AD  - Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, 060-0812, 
      Hokkaido, Japan.
LA  - eng
GR  - 18K18351/Japan Society for the Promotion of Science/
GR  - JPMJCR17H1/Core Research for Evolutional Science and Technology/
PT  - Journal Article
PT  - Review
DEP - 20191120
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Drug Carriers)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/administration & dosage/pharmacology/therapeutic use
MH  - Drug Carriers/*chemistry
MH  - Endothelial Cells/*drug effects/pathology
MH  - Humans
MH  - Nanoparticles/*chemistry
MH  - Neoplasms/*drug therapy/pathology
MH  - Neovascularization, Pathologic/*drug therapy
PMC - PMC6928777
OTO - NOTNLM
OT  - anti-angiogenic therapy
OT  - drug delivery system
OT  - nanoparticles
OT  - nucleic acids
OT  - tumor endothelial cells
COIS- The authors declare no conflict of interest.
EDAT- 2019/11/24 06:00
MHDA- 2020/04/14 06:00
PMCR- 2019/12/01
CRDT- 2019/11/24 06:00
PHST- 2019/10/22 00:00 [received]
PHST- 2019/11/14 00:00 [revised]
PHST- 2019/11/18 00:00 [accepted]
PHST- 2019/11/24 06:00 [entrez]
PHST- 2019/11/24 06:00 [pubmed]
PHST- 2020/04/14 06:00 [medline]
PHST- 2019/12/01 00:00 [pmc-release]
AID - ijms20235819 [pii]
AID - ijms-20-05819 [pii]
AID - 10.3390/ijms20235819 [doi]
PST - epublish
SO  - Int J Mol Sci. 2019 Nov 20;20(23):5819. doi: 10.3390/ijms20235819.